Yersinia enterocolitica causes a spectrum of diseases ranging from those confined to the intestinal tract to fatal septicemic disease (1, 2, 6, 11, 14) . Serotypes isolated in Europe usually produce self-limiting gastroenteritis, whereas American strains, especially serotype 0:8, are more likely to cause systemic infections (3, 4, 8, 9) . Y. enterocolitica 0:8 strains are also virulent for mice. After being inoculated orally with these strains, mice experience systemic infections involving such organs of the reticuloendothelial system as Peyer's patches, mesenteric lymph nodes, livers, and spleens (5) . Virulent Y. enterocolitica strains harbor a plasmid which encodes a number of virulenceassociated determinants (16) ; loss of this plasmid leads to attenuation in mice (12, 19) . Salmonella spp., including Salmonella typhimurium, also cause invasive infections in mice following oral challenge (7) . Virulent salmonellae can be attenuated by the introduction of stable mutations in genes in the aromatic biosynthetic pathway (10) . Such mutants (aro mutants) require aromatic compounds, including the aromatic amino acids para-aminobenzoic acid and dihydroxybenzoate, for growth. Since some of these compounds are in short supply in vivo, the bacteria are capable of only limited replication before being cleared from the host (13, 15) . Extensive studies on the immunological properties of Salmonella aroA mutants have shown them to be excellent oral vaccines (10, 13, 15 (18) . Gastric acidity was neutralized before all oral inoculations by the oral administration of 0.2 ml of 7.5% sodium bicarbonate. The 50% lethal doses (LD50s) were calculated by the method of Reed and Muench (17) .
Y. enterocolitica strains were tested for virulence after being administered orally to BALB/c mice. 8081 was virulent, with an LD50 of log1o 7 A dose-response effect was observed ( Table 1) , showing that the mean time to death increased as the immunizing dose of YAM.1 increased. Immunized animals died between days 8 and 17, whereas controls were all dead by day 8. Two immunized animals survived the challenge. While these results indicate that immunization delayed death from a virulent infection, most of the mice still died. Accordingly, we investigated the immunizing properties of multiple oral doses of YAM.1. Forty BALB/c mice were immunized orally with log1o 9.96, 10.75, and 10.52 doses of YAM.1 at 3-day intervals. A control group of mice were dosed on each occasion with phosphate-buffered saline. On day 28 after the final immunization, the mice were challenged orally with a maximum log10 8.45 dose of 8081 to determine the LD50. The LD50 value obtained for the control group treated with phosphate-buffered saline was log10 6.88. Only four animals in the immunized group died, giving an LD50 of more than log1o 8.55 (Table 2 ). The survival rate for immunized animals These results show that Y. enterocolitica 0:8 aroA mutants are less effective oral vaccines than are S. typhimurium aroA mutants: several doses of the Yersinia aroA mutants are required for measurable protection, whereas Salmonella aroA mutants confer protection after a single dose (15) . This may result from the poor persistence of the Yersinia mutants. We are currently assessing the immune responses in the protected animals to examine in detail the mechanisms of protection. It will be interesting to see how Y. enterocolitica aroA mutants behave in other infection models and to see if aroA mutants of other Yersinia species are also attenuated.
It is possible that aro and other metabolic lesions may provide a common route by which to attenuate a variety of bacterial pathogens. We have recently shown that aroA mutants of Bordetella pertussis are highly attenuated and immunogenic in a mouse aerosol challenge system (M. Roberts, D. Maskell, P. Novotny, and G. Dougan, submitted for publication). Thus it may soon be possible to develop a range of rationally attenuated bacteria for use as immunological tools and experimental vaccines.
